Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Casi Phrmactcls Inc (CASI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results

ROCKVILLE, Md. , Nov. 14, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (the "Company") (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results

CASI Pharmaceuticals, Inc. (the "Company") (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other...

CASI : 2.60 (+5.26%)
Cancer Immunotherapy Technology Projected to Create Further Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at a CAGR of 14.5 percent from the time period of 2016...

CLDX : 2.91 (+2.11%)
ARQL : 1.42 (+6.77%)
RGBP : 0.0900 (+21.62%)
RGBPP : 0.0600 (+33.33%)
ECYT : 5.09 (+7.16%)
CASI : 2.60 (+5.26%)
Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx - Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tandem Diabetes Care, Inc....

VHC : 4.05 (-11.96%)
TNDM : 2.93 (+8.12%)
ROKA : 0.95 (unch)
PZRX : 0.66 (+3.13%)
SAEX : 1.81 (+9.04%)
CASI : 2.60 (+5.26%)
CASI Pharmaceuticals, Capital Raise, Analysts Review, Product Development, and Guidance

NEW YORK, NY / ACCESSWIRE / October 31, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders

ROCKVILLE, Md. , Oct. 13, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (the "Company") (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders

CASI Pharmaceuticals, Inc. (the "Company") (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other...

CASI : 2.60 (+5.26%)
CASI Provides Pipeline Development Update

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today provided an update to its pipeline.

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment Conference

ROCKVILLE, Md. , Sept. 6, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment Conference

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs announces it will present at the 19th Annual...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Reports Second Quarter 2017 Financial Results

ROCKVILLE, Md. , Aug. 14, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Reports Second Quarter 2017 Financial Results

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today reported financial results for the three...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma (CCOC)

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs announces a poster presentation on ENMD-2076...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today reported the availability of an abstract...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Reports First Quarter 2017 Financial Results

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today reported financial results for the three...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, reported today that along with the investigators...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Reports 2016 Fourth Quarter And Full Year Financial Results

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today reported financial results for the three...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting

ROCKVILLE, Md. , March 28, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical...

CASI : 2.60 (+5.26%)
CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announced today two poster presentations at...

CASI : 2.60 (+5.26%)

Van Meerten Stock Picks

My 5 Favorite Small Caps
This morning I wanted to find the 5 Small Cap Stocks that had the best returns over the past year but still appeared to have some more room to climb.
SEDG -0.20 , GDOT +0.11 , CTRL -1.36 , ESIO -0.65 , QNST +0.23
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 -0.06% ) this morning are down 0.06% on concern Special Counsel Mueller's criminal investigation between Trump campaign officials and Russia is deepening. Two people familiar with the matter... Read More

Chart of the Day

Chart of the Day

D R Horton (DHI) is the Barchart Chart of the Day.  The home builder has a Trend Spotter buy signal, a Weighted Alpha of 77.13+ and gained 68.46% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed Friday with most contracts 4 – 6 1/2 cents higher, as Dec came back to only lose a half cent on the week. Pre-weekend profit taking gets some of the credit. The CFTC report on Friday showed the spec funds holding a new recor...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart